The growing ecosystem of companies involved in the leverage of AI technologies on health care and drug development needs a new evaluation scheme, more complicated than the typical evaluation schemes for startups in other sectors
The growing ecosystem of companies involved in the leverage of AI technologies on health care and drug development needs a new evaluation scheme, more complicated than the typical evaluation schemes for startups in other sectors